is semaglutide going to stop being compounded FDA moving restrict mass-marketed GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified Troubling Findings in Study of

The compound's selectivity profile minimizes concerns about off-target effects, but investigators should consider potential interactions with other NAD+-modulating interventions or compounds that affect methylation metabolism

The 7,319 patients taking a GLP-1 for 5 years showed a significantly lower risk of developing dry AMD: 63 percent lower than patients on metformin, 58 percent lower risk than patients on insulin, and 54 percent lower risk than those taking a SGLT2i

The field is so far proving to be unpredictable

Im the opposite

Moreover, an increased DPP4 production from adipocytes is observed in both type 1 and T2DM [140]